2023年至今,中国创新药license-out交易“狂飙”之中,一道“分水岭”也愈发明显——高额首付款的BD交易,似乎更加青睐临床1期及之前的早期资产。2023年交易首付款TOP10的license-out交易中,一半的资产都处于临床1/2期及之前阶段,而到2024年及2025年上半年,这一比例上升到80%,其中包括同润生物CD3/CD19双抗、锐格医药下一代CDK抑制剂、恩沐生物三抗等刷新...
Source Link2023年至今,中国创新药license-out交易“狂飙”之中,一道“分水岭”也愈发明显——高额首付款的BD交易,似乎更加青睐临床1期及之前的早期资产。2023年交易首付款TOP10的license-out交易中,一半的资产都处于临床1/2期及之前阶段,而到2024年及2025年上半年,这一比例上升到80%,其中包括同润生物CD3/CD19双抗、锐格医药下一代CDK抑制剂、恩沐生物三抗等刷新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.